Mantle irradiation alone for clinical stage I-II Hodgkin's disease: Long-term follow-up and analysis of prognostic factors in 261 patients

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 230-240

  Wirth, Andrew ^a   Chao, M ^a   Corry, J ^a   Laidlaw, C ^a   Yuen, K ^a   Ryan, G ^a   Byram, D ^a   Davis, S ^a   Kiffer, J ^a   Quong, G ^a   Liew, K ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TREATMENT FAILURE;

EID: 0032944894     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.230     Document Type: Article

References (51)

1. Rosenberg SA: The management of Hodgkin's disease: Half a century of change. The Kaplan Memorial Lecture. Ann Oncol 7:555-560, 1996
2. Mauch PM, Kalish LA, Marcus KC, et al: Long-term survival in HD: Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1:33-42, 1995
3. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
4. Smitt MC, Buzydlowski J, Hoppe RT: Over 20 years of progress in radiation oncology: Hodgkin's disease. Semin Oncol 7:127-134, 1997
5. Mauch PM: Controversies in the management of early stage Hodgkin's disease. Blood 83:318-329, 1994
6. Reus K, Engert H, Tesch H, et al: Current clinical trials in Hodgkin's disease. Ann Oncol 7:S109-S113, 1996 (suppl 4)
7. Tubiana M, Henry-Amar M, Carde P, et al: Toward comprehensive management tailored to prognostic factors of patients with clinical stages I-II in Hodgkin's disease: The EORTC lymphoma group controlled clinical trials 1964-87. Blood 73:47-56, 1989
8. Bodis S, Kraus MD, Pinkus G, et al: Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 15:3060-3066, 1997
9. Abrahamsen AF, Hannisdal E, Nome O, et al: Clinical stage I and II Hodgkin's disease: Long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol 7:145-150, 1996
10. Glimelius B, Kälkner M, Enbald G, et al for the Swedish Lymphoma Study Group: Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Programme experience. Ann Oncol 5:809-816, 1994
11. Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, et al for the Princess Margaret Hospital Lymphoma Group: Radiation therapy in clinical stage I and II Hodgkin's disease. Eur J Cancer 28:1841-1846, 1992
12. Noordijk EM, Carde P, Hagenbeek A, et al: Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease: Six-year results of the EORTC-GPMC controlled clinical trials "H7-VF," "H7-F," "H7-U". Int J Radiat Oncol Biol Phys 39:173, 1997 (suppl)
13. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: The Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
14. Dixon WJ, Brown MB, Engelman L, et al: BMDP Statistical Software Manual. Berkeley, CA, University of California Press, 1988
15. S-PLUS [computer program]. Version 4.0 for Windows. Seattle. WA, StatSci, a division of MathSoft, Inc., 1995
16. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
17. Noordijk EM, Carde P, Mandard A-M, et al: Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. Ann Oncol 5:s107-s112, 1994 (suppl 2)
18. Cosset JM, Henry-Amar M, Meervaldt JH, et al: The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 28A:1847-1850, 1992
19. Mauch PM, Canellos GP, Shulman LN, et al: Mantle irradiation alone for selected patients with laparotomy-staged IA and IIA Hodgkin's disease: Preliminary results of a prospective trial. J Clin Oncol 13:947-952, 1995
20. Mauch P, Larson D, Osteen R, et al: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 8: 257-265, 1990
21. Leibenhaut MH, Hoppe RT, Efron B, et al: Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 7: 81-91, 1989
22. Horning SJ, Hoppe RT, Mason J, et al: Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736-1744, 1997
23. Mauch PM, Kalish LA, Marcus KC, et al: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625-2632, 1996
24. Hoppe RT: HD: Complications of therapy and excess mortality. Ann Oncol 8:s115-s118, 1997 (suppl 1)
25. Shore T, Nelson N, Weinerman B: A meta-analysis of stages I and II Hodgkin's disease. Cancer 65:1155-1160, 1990
26. Specht L, Gray RG, Clarke MJ, et al: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16:830-843, 1998
27. Cimino G, Biti GP, Cartoni C, et al: Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy. Eur J Cancer 28:1853-1855, 1992
28. Rueda A, Alba E, Ribelles N, et al: Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: A pilot study. J Clin Oncol 15:1118-1122, 1997
29. Hirsch A, Vander Els N, Straus DJ, et al: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14:1297-1305, 1996
30. Steinherz LJ, Steinherz PG, Tan CTC, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
31. Longo DL: Chemotherapy alone in the treatment of patients with early stage HD. Ann Oncol 7:s85-s89, 1996 (suppl 4)
32. Longo DL, Glatstein E, Duffey PL, et al: Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9:906-917, 1991
33. Biti GP, Cimino G, Cartoni C, et al: Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378-382, 1992
34. Pavlovsky S, Schvartzman E, Lastiri F, et al: Randomized trial of CVPP for three versus six cycles in favorable-prognostic and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol 15:2652-2658, 1997
35. Biti G, Cellai E, Magrini SM, et al: Second solid tumors and leukemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29:25-31, 1994
36. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al: Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143, 1992
37. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease. Ann Oncol 3:s117-s128, 1992
38. Rosenberg SA, Kaplan HS: The evolution and summary results of the Stanford randomized clinical trials of the management of HD: 1962-1984. Int J Radiat Oncol Biol Phys 11:5-22, 1985
39. Sutcliffe SB, Gospodarowicz MK. Bergsagel DE, et al: Prognostic groups for management of localized Hodgkin's disease. J Clin Oncol 3:393-401, 1985
40. Tubiana M, Henry-Amar M, van der Werf-Messing B, et al for the Radiotherapy-Chemotherapy Group of the EORTC: A multifactor analysis of prognostic factors in early stage HD. Int J Radiat Oncol Biol Phys 11:23-30, 1985
41. Johnson DW, Hoppe RT, Cox RS, et al: Hodgkin's disease limited to intrathoracic sites. Cancer 52:8-13, 1983
42. van der Werf-Messing B: Morbus Hodgkin's disease, stages I and II: Trial of the European Organization for Research on Treatment of Cancer. Natl Cancer Inst Monogr 36:331-386, 1973
43. Schwartz RS: Hodgkin's disease: Time for a change. N Engl J Med 337:495-496, 1997
44. Crennan E, D'Costa I, Liew K, et al: Lymphocyte predominant Hodgkin's disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 31:333-337, 1995
45. Sutcliffe SB, Gospodarowicz MK, Bush RS, et al: Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 4:211-223, 1985
46. Bonadonna G, Valagussa P, Santoro A: Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy. Cancer Surv 4:439-458, 1985
47. Behar RA, Horning SJ, Hoppe RT: Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 25:771-776, 1993
48. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993
49. Banarter M, Griesshammer M, Binder T, et al: New diagnostic imaging procedures in Hodgkin's disease. Ann Oncol 7:S55-S59, 1996 (suppl 4)
50. Moody AM, Williams MV: Radiation dose in Hodgkin's disease: Are we overtreating? Clin Oncol 9:155-157, 1997
51. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late morbidity from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993